{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:22:11Z","timestamp":1787242931247,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01508-w","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:52:25Z","timestamp":1766055145000},"page":"221-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo\/Vitro Evidence"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2583-7704","authenticated-orcid":false,"given":"Matthieu","family":"Gassiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Wauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"1508_CR1","first-page":"1","volume":"881","author":"Control and surveillance of African trypanosomiasis","year":"1998","unstructured":"Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. 1998;881:1\u2013114.","journal-title":"Report of a WHO Expert Committee."},{"key":"1508_CR2","unstructured":"Neglected diseases data interactive map 2018. World Health Organization. Cited December 2024. https:\/\/apps.who.int\/neglected_diseases\/ntddata\/hat\/hat.html. Accessed 25 Oct 2025."},{"issue":"11","key":"1508_CR3","doi-asserted-by":"publisher","first-page":"e1665","DOI":"10.1016\/S2214-109X(22)00338-2","volume":"10","author":"VKB Kumesu","year":"2022","unstructured":"Kumesu VKB, Kalonji WM, Bardonneau C, Mordt OV, Tete DN, Blesson S, et al. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single\u2013arm, open\u2013label, phase 2\u20133 trial. Lancet Glob Health. 2022;10(11):e1665\u201374.","journal-title":"Lancet Glob Health"},{"key":"1508_CR4","first-page":"257","volume":"6","author":"JR Franco","year":"2014","unstructured":"Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African trypanosomiasis. Clin Epidemiol. 2014;6:257\u201375.","journal-title":"Clin Epidemiol"},{"key":"1508_CR5","unstructured":"Sanofi. Fexinidazole tablets [package insert]. U.S. Food and Drug Administration website. Revised September 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214429s003s004lbl.pdf. Accessed 25 Oct 2025."},{"issue":"12","key":"1508_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, et al. Fexinidazole\u2013a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4(12):e923.","journal-title":"PLoS Negl Trop Dis"},{"key":"1508_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","volume":"53","author":"A Tarral","year":"2014","unstructured":"Tarral A, Blesson S, Mordt OV, Torreele E, Sassella D, Bray MA, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first\u2013in\u2013human studies. Clin Pharmacokinet. 2014;53:565\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1508_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/ph15020128","volume":"15","author":"M Imran","year":"2022","unstructured":"Imran M, Khan SA, Alshammari MK, Alqahtani AM, Alanazi TA, Kamal M, et al. Discovery, development, inventions and patent review of fexinidazole: the first all\u2013oral therapy for human African trypanosomiasis. Pharmaceuticals. 2022;15(2):128.","journal-title":"Pharmaceuticals"},{"key":"1508_CR9","unstructured":"WHO model list of essential medicines \u2013 21st list, 2019. World Health Organization. 2019. https:\/\/www.who.int\/publications\/i\/item\/WHOMVPEMPIAU2019.06. Accessed 25 Oct 2025."},{"key":"1508_CR10","unstructured":"Sanofi. Fexinidazole tablets [package insert]. U.S. Food and Drug Administration website. Revised December 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214429s001lbl.pdf. Accessed 25 Oct 2024."},{"issue":"4","key":"1508_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1365-2125.2009.03386.x","volume":"67","author":"R Hyland","year":"2009","unstructured":"Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, et al. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol. 2009;67(4):445\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1508_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","volume":"91","author":"K Dooley","year":"2012","unstructured":"Dooley K, Bliven-Sizemore E, Weiner M, Lu Y, Nuermberger E, Hubbard W, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):881\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1508_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2125.2008.03201.x","volume":"66","author":"B Link","year":"2008","unstructured":"Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, et al. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008;66(4):473\u201384.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1508_CR14","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1124\/dmd.115.065326","volume":"43","author":"D Ramsden","year":"2015","unstructured":"Ramsden D, Zhou J, Tweedie DJ. Determination of a degradation constant for CYP3A4 by direct suppression of mRNA in a novel human hepatocyte model, HepatoPac. Drug Metab Dispos. 2015;43(9):1307\u201315.","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"1508_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","volume":"43","author":"J Dingemanse","year":"2004","unstructured":"Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43(15):1089\u2013115.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1508_CR16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.510","volume":"100","author":"OA Fahmi","year":"2016","unstructured":"Fahmi OA, Chen L, Hurst S, Obach RS, Shebley M, Silva J, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther. 2016;100(6):597\u2013610.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1508_CR17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"M Oscarson","year":"2006","unstructured":"Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Pharmacodynamics of carbamazepine\u2013mediated induction of CYP3A4, CYP1A2, and P\u2013glycoprotein. Clin Pharmacol Ther. 2006;79(6):540\u201350.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01508-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:20Z","timestamp":1770179720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01508-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GM, PB, FDS, and ON are employees of Sanofi and may hold stocks and\/or stock options in the company. ES was an employee of Sanofi at the time of the study. All authors were involved in the design, conduct, analysis, and interpretation of the study, which was funded by Sanofi. While this may be perceived as a potential professional interest, the authors affirm that the study was conducted with scientific rigor and transparency. The authors declare no personal relationships, beliefs, or other non-financial interests that could be perceived to have influenced the work reported in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study (EudraCT No. 2021\u2013004533\u201336) was conducted in compliance with the Declaration of Helsinki (World Medical Association) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practices guidelines (ICH E6 R2). The study also conformed to the European and French regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent before undergoing any study-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not publicly available to protect the privacy and confidentiality of study participants. Data may be available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"GM performed formal analyses and interpretation of results. ON performed the formal analyses. PB and FDS conducted the in vitro study assessments. VW carried out the bioanalytical assays. ES conceptualised the study and interpreted the results. HS served as the principal investigator of the study. GM and ES contributed to writing-review and editing of the manuscript. All authors reviewed the manuscript critically and approved the final version. All authors agreed to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}